Jakavi

Ruxolitinib, the active ingredient in Jakavi, is a Janus kinase (JAK) inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of myelofibrosis and polycythemia vera in adult patients, helping to control disease‑related symptoms and blood counts.

GNH USA supplies Jakavi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Jakavi (ruxolitinib) is used in the management of myeloproliferative neoplasms, targeting abnormal blood cell production.

- Myelofibrosis: reduces spleen size and improves constitutional symptoms. - Polycythemia vera: helps maintain target hematocrit and reduces phlebotomy requirements. - Symptom burden in myeloproliferative disorders: alleviates fatigue, night sweats, and pruritus.

Jakavi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Anemia: decreased red blood cell count. - Thrombocytopenia: reduced platelet levels. - Neutropenia: lowered neutrophil count. - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of sickness. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Infections: opportunistic or severe infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Pulmonary hypertension: rare increase in pulmonary arterial pressure. - Secondary malignancies: potential development of new cancers.

Before prescribing Jakavi, clinicians should consider several safety precautions to minimize risks.

- Baseline blood counts: obtain CBC to assess anemia, platelets, neutrophils. - Infection risk: screen for active infections and monitor for signs during therapy. - Liver function: evaluate hepatic enzymes prior to initiation and periodically. - Cardiovascular assessment: monitor for hypertension or pulmonary hypertension. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with patient. - Store at ambient temperature: keep tablets below 25°C in original packaging, protect from moisture.

Jakavi can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ruxolitinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): potential for altered bleeding risk. - Vaccines (live attenuated): reduced vaccine efficacy. - Other immunosuppressants: additive risk of infection. - CYP3A4 substrates with narrow therapeutic index: monitor plasma levels.